The Benefits of LACRISERT®
Artificial tears and other products are less convenient for people suffering from Dry Eye because they require repeated applications.1-3 Just one LACRISERT® insert placed in each eye once daily* can usually relieve Dry Eye symptoms.4
LACRISERT® slowly begins to dissolve within minutes of insertion and lasts, on average, from 14 to 18 hours, providing all-day relief.4
Safe, Preservative-Free Formula
LACRISERT® is well tolerated and has been approved for over 25 years.4,5 There are no preservatives, so there is no eye sensitivity, irritation, or pain with continued use.1,4
LACRISERT® dissolves slowly, extending the amount of time that tears remain on the surface of your eye and thickening the tear film for continuous protection.4,6
Progressive visual deterioration which occurs at times may be retarded, halted, or sometimes reversed.4
Safe With Artificial Tears
If your eye is too dry, you may need added moisture to start dissolving LACRISERT®.2,7 You can use artificial tear products at the same time as LACRISERT® to speed along the process.8,9
LACRISERT® can be easily placed in just 6 simple steps. A study shows that 91% of rheumatoid arthritis patients learned to successfully place and retain the small insert after just a few tries.1
LACRISERT® is covered by most insurance plans. Just drop your written prescription off at any local pharmacy. Click here for a rebate coupon for up to $60 off your prescription co-pay.
This video will explain more about the benefits of LACRISERT®.
*For most Dry Eye sufferers, one LACRISERT® inserted in each eye in the morning lasts the entire day. But some people may need to use it twice a day for symptom relief.4
Indications and Usage
LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.
Important Safety Information
LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT®.
The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.
Talk to your doctor if you have side effects that bother you or that do not go away. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
References: 1. Hill JC. Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol. 1989;73(2):151-154. 2. Katz JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85(8):787-793.
3. Werblin TP, Rheinstrom SD, Kaufman HE. The use of slow-release artificial tears in the long-term management of keratitis sicca. Ophthalmology. 1981;88(1):78-81. 4. Lacrisert [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2007. 5. Data on File. Aton Pharma, Inc. 6. Breslin CW, Katz J, Kaufman HE, Katz I. Slow release artificial tears. In: Leopold IH, Burns RP, eds. Symposium on Ocular Therapy. New York, NY: John Wiley & Sons; 1977;10:77-83. 7. Høvding G, Aasved H. Slow-release artificial tears (SRAT) in dry eye disease: report of a preliminary clinical trial. Acta Ophthalmol. 1981;59:842-846.
8. Lacrisert Clinical White Paper. Available at: http://www.lacrisert.com/attachments/LacrisertClinicalWhitePaper.pdf. Accessed January 5, 2009. 9. Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology. 4th ed. Boston, MA: Butterworth-Heinemann;2001:325.